Hexameric MnII Dendrimer as MRI Contrast Agent

被引:55
|
作者
Zhu, Jiang [1 ,2 ]
Gale, Eric M. [1 ]
Atanasova, Iliyana [3 ]
Rietz, Tyson A. [1 ]
Caravan, Peter [1 ]
机构
[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging,Dept Radi, Charlestown, MA 02141 USA
[2] North Sichuan Med Coll, Sichuan Key Lab Med Imaging, Nanchong, Peoples R China
[3] MIT, Cambridge, MA 02141 USA
关键词
dendrimers; imaging agents; manganese; magnetic resonance imaging; NMR spectroscopy; NEPHROGENIC SYSTEMIC FIBROSIS; METAL-COMPLEXES; WATER-EXCHANGE; MAGNETIC-FIELD; RESONANCE; RELAXATION; RELAXIVITY; GADOLINIUM; DISEASE; LIVER;
D O I
10.1002/chem.201403883
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
A Mn-II chelating dendrimer was prepared as a contrast agent for MRI applications. The dendrimer comprises six tyrosine-derived [Mn(EDTA)(H2O)](2-) moieties coupled to a cyclotriphosphazene core. Variable temperature (ONMR)-O-17 spectroscopy revealed a single water co-ligand per Mn-II that undergoes fast water exchange (k(ex)=(3.0 +/- 0.1)x10(8)s(-1) at 37 degrees C). The 37 degrees C per Mn-II relaxivity ranged from 8.2 to 3.8mM(-1)s(-1) from 0.47 to 11.7T, and is sixfold higher on a per molecule basis. From this field dependence a rotational correlation time was estimated as 0.45(+/- 0.02)ns. The imaging and pharmacokinetic properties of the dendrimer were compared to clinically used [Gd(DTPA)(H2O)](2-) in mice at 4.7T. On first pass, the higher per ion relaxivity of the dendrimer resulted in twofold greater blood signal than for [Gd(DTPA)(H2O)](2-). Blood clearance was fast and elimination occurred through both the renal and hepatobiliary routes. This Mn-II containing dendrimer represents a potential alternative to Gd-based contrast agents, especially in patients with chronic kidney disease where the use of current Gd-based agents may be contraindicated.
引用
收藏
页码:14507 / 14513
页数:7
相关论文
共 50 条
  • [21] ABDOMINAL MRI USING A NEGATIVE CONTRAST AGENT
    BACHGANSMO, T
    DUPAS, B
    GAYETDELACROIX, M
    LAMBRECHTS, M
    BRITISH JOURNAL OF RADIOLOGY, 1993, 66 (785): : 420 - 425
  • [22] Acute infarct selective MRI contrast agent
    Robert Kirschner
    Akos Varga-Szemes
    Tamas Simor
    Pal Suranyi
    Pal Kiss
    Balazs Ruzsics
    Brigitta C. Brott
    Ada Elgavish
    Gabriel A. Elgavish
    The International Journal of Cardiovascular Imaging, 2012, 28 : 285 - 293
  • [23] MRI of the liver: choosing the right contrast agent
    Welle, Christopher L.
    Guglielmo, Flavius F.
    Venkatesh, Sudhakar K.
    ABDOMINAL RADIOLOGY, 2020, 45 (02) : 384 - 392
  • [24] Microbubbles as a novel contrast agent for brain MRI
    Cheung, Jerry S.
    Chow, April M.
    Guo, Hua
    Wu, Ed X.
    NEUROIMAGE, 2009, 46 (03) : 658 - 664
  • [25] Acute infarct selective MRI contrast agent
    Robert Kirschner
    Akos Varga-Szemes
    Tamas Simor
    Suranyi, Pal
    Kiss, Pal
    Ruzsics, Balazs
    Brott, Brigitta C.
    Elgavish, Ada
    Elgavish, Gabriel A.
    INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 2012, 28 (02): : 285 - 293
  • [26] Safety and Efficacy in Selecting a Contrast Agent for MRI
    Maki, Jeffrey H.
    APPLIED RADIOLOGY, 2015, 44 (09)
  • [27] A zinc-activated MRI contrast agent
    Major, Jody L.
    Meade, Thomas J.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 802 - 802
  • [28] A scale to measure MRI contrast agent sensitivity
    Alvares, Rohan D. A.
    Szulc, Daniel A.
    Cheng, Hai-Ling M.
    SCIENTIFIC REPORTS, 2017, 7
  • [29] A LIPOSOMAL MRI CONTRAST AGENT - PHOSPHATIDYLETHANOLAMINE DTPA
    GRANT, CWM
    KARLIK, S
    FLORIO, E
    MAGNETIC RESONANCE IN MEDICINE, 1989, 11 (02) : 236 - 243
  • [30] Safety and Efficacy in Selecting a Contrast Agent for MRI
    Maki, Jeffrey H.
    APPLIED RADIOLOGY, 2015, 44 (10) : 1 - +